Literature DB >> 29203544

Mapping Protective Regions on a Three-Dimensional Model of the Moraxella catarrhalis Vaccine Antigen Oligopeptide Permease A.

Antonia C Perez1,2, Antoinette Johnson1,2, Ziqiang Chen3, Gregory E Wilding3, Michael G Malkowski4,5, Timothy F Murphy6,2,7.   

Abstract

A vaccine against Moraxella catarrhalis would reduce tremendous morbidity, mortality, and financial burden by preventing otitis media in children and exacerbations of chronic obstructive pulmonary disease (COPD) in adults. Oligopeptide permease A (OppA) is a candidate vaccine antigen that is (i) a nutritional virulence factor expressed on the bacterial cell surface during infection, (ii) widely conserved among strains, (iii) highly immunogenic, and (iv) a protective antigen based on its capacity to induce protective responses in immunized animals. In the present study, we show that the antibodies to OppA following vaccination mediate accelerated clearance in animals after pulmonary challenge. To identify regions of OppA that bind protective antibodies, truncated constructs of OppA were engineered and studied to map regions of OppA with surface-accessible epitopes that bind high-avidity antibodies following vaccination. Protective epitopes were located in the N and C termini of the protein. Immunization of mice with constructs corresponding to these regions (T5 and T8) induced protective responses. Studies of overlapping peptide libraries of constructs T5 and T8 with OppA immune serum identified two discrete regions on each construct. These potentially protective regions were mapped on a three-dimensional computational model of OppA, where regions with solvent-accessible amino acids were identified as three potentially protective epitopes. In all, these studies revealed two regions with three specific epitopes in OppA that induce potentially protective antibody responses following vaccination. Detection of antibodies to these regions could serve to guide vaccine formulation and as a diagnostic tool for monitoring development of protective responses during clinical trials.
Copyright © 2018 American Society for Microbiology.

Entities:  

Keywords:  COPD; Moraxella catarrhalis; OppA; otitis media; surface antigens; vaccines

Mesh:

Substances:

Year:  2018        PMID: 29203544      PMCID: PMC5820933          DOI: 10.1128/IAI.00652-17

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  43 in total

Review 1.  Control systems and decision making for antibody production.

Authors:  Christopher C Goodnow; Carola G Vinuesa; Katrina L Randall; Fabienne Mackay; Robert Brink
Journal:  Nat Immunol       Date:  2010-07-20       Impact factor: 25.606

2.  Role of the oligopeptide permease ABC Transporter of Moraxella catarrhalis in nutrient acquisition and persistence in the respiratory tract.

Authors:  Megan M Jones; Antoinette Johnson; Mary Koszelak-Rosenblum; Charmaine Kirkham; Aimee L Brauer; Michael G Malkowski; Timothy F Murphy
Journal:  Infect Immun       Date:  2014-08-25       Impact factor: 3.441

3.  Vaccine development for Moraxella catarrhalis: rationale, approaches and challenges.

Authors:  Timothy F Murphy
Journal:  Expert Rev Vaccines       Date:  2009-06       Impact factor: 5.217

4.  Improving immunity to Haemophilus influenzae in children with chronic suppurative lung disease.

Authors:  Susan J Pizzutto; Stephanie T Yerkovich; John W Upham; Belinda J Hales; Wayne R Thomas; Anne B Chang
Journal:  Vaccine       Date:  2014-11-22       Impact factor: 3.641

5.  Burden of acute otitis media on Canadian families.

Authors:  Eve Dubé; Philippe De Wals; Vladimir Gilca; Nicole Boulianne; Manale Ouakki; France Lavoie; Richard Bradet
Journal:  Can Fam Physician       Date:  2011-01       Impact factor: 3.275

Review 6.  PCVs in individuals at increased risk of pneumococcal disease: a literature review.

Authors:  Mark A Fletcher; Paul Balmer; Eric Bonnet; Nathalie Dartois
Journal:  Expert Rev Vaccines       Date:  2015-07       Impact factor: 5.217

Review 7.  The burden of otitis media.

Authors:  J O Klein
Journal:  Vaccine       Date:  2000-12-08       Impact factor: 3.641

8.  Molecular pathogenesis of infections caused by Moraxella catarrhalis in children.

Authors:  Sara Bernhard; Violeta Spaniol; Christoph Aebi
Journal:  Swiss Med Wkly       Date:  2012-10-29       Impact factor: 2.193

Review 9.  Burden of disease caused by otitis media: systematic review and global estimates.

Authors:  Lorenzo Monasta; Luca Ronfani; Federico Marchetti; Marcella Montico; Liza Vecchi Brumatti; Alessandro Bavcar; Domenico Grasso; Chiara Barbiero; Giorgio Tamburlini
Journal:  PLoS One       Date:  2012-04-30       Impact factor: 3.240

10.  Assessment of antibody level and avidity against Bordetella pertussis in a cohort of Egyptian individuals aged 1-18 years.

Authors:  Nihal M Ibrahim; Ebtsam M El-Kady; Somiaa A Eissa; Ahmed F Wahby
Journal:  J Adv Res       Date:  2015-03-21       Impact factor: 10.479

View more
  1 in total

Review 1.  Panel 8: Vaccines and immunology.

Authors:  Mark R Alderson; Tim Murphy; Stephen I Pelton; Laura A Novotny; Laura L Hammitt; Arwa Kurabi; Jian-Dong Li; Ruth B Thornton; Lea-Ann S Kirkham
Journal:  Int J Pediatr Otorhinolaryngol       Date:  2019-12-18       Impact factor: 1.675

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.